Assure Sentinel: COVID-19 Screening for Safe Organizations
Kailos Assure creates safe organizations by regularly testing your workforce for SARS-CoV-2.
The process works by combining, or pooling, dozens of samples together for testing with TargetRich™, our proprietary method of specifically capturing the SARS-COV-2 genome. Once captured, our sequencers go to work looking for the presence of SARS-COV-2, the virus that causes COVID-19.
Using information about your workforce, safety practices and local infection rates, we generate testing programs that help optimize the frequency and depth of testing for your organization.
What is Sentinel Testing?
Symptomatic persons should be tested in a healthcare facility and quarantined.
It’s the people that have been exposed to the virus knowingly or not that need to be identified.
But, that is a lot of people to test…
The key is to test portions of your workforce on a regular basis. With each cycle of testing, those that are infected are identified and quarantined. Then, with each cycle of testing, identify more of those that were infected by their community or co-workers.
Sentinel testing does just that. A couple of times per week, collect samples from a percentage of your workforce and send them in for testing. Next week do it again. The following week, do it again.
Keep this up and you will reduce the number of infected people and make your organization a safer place!
How are samples collected for testing?
To test routinely, it has to be easy and painless to provide a sample.
ViraWash™ accomplishes that. Instructions provided in the video below describe how a simple gargle with saline provides a sample that can be screened for the presence or absence of SARS-COV-2, the virus that causes COVID-19.
Is This Test Approved By The FDA?
Kailos’ Assure Sentinel™ COVID-19 testing has been submitted to the FDA for Emergency Use Authorization (EUA). Our internal testing shows that Assure Sentinel™ testing is comparable in performance to RT-PCR assays currently authorized by the FDA.
For more information on the FDA Emergency Use Authorizations as they apply to COVID-19 testing:
"On February 4, 2020, the HHS Secretary determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. On the basis of this determination, the Secretary then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19." -FDA Emergency Use Authorization